Fluoroalkoxylated C-3 and C-9 (S)-12-bromostepholidine analogues with D1R antagonist activity

  • Bioorg Chem. 2023 Dec:141:106862. doi: 10.1016/j.bioorg.2023.106862.
Hari K Namballa  1 Ann M Decker  2 Michael Dorogan  1 Ashok Gudipally  3 Jakub Goclon  1 Wayne W Harding  4
Affiliations
  • 1. Department of Chemistry, Hunter College, City University of New York, 695 Park Avenue, NY 10065, United States.
  • 2. Center for Drug Discovery, RTI International, Research Triangle Park, NC 27709, United States.
  • 3. Department of Chemistry, Hunter College, City University of New York, 695 Park Avenue, NY 10065, United States; Program in Chemistry, CUNY Graduate Center 365 5th Avenue, New York, NY 10016, United States.
  • 4. Department of Chemistry, Hunter College, City University of New York, 695 Park Avenue, NY 10065, United States; Program in Chemistry, CUNY Graduate Center 365 5th Avenue, New York, NY 10016, United States; Program in Biochemistry, CUNY Graduate Center 365 5th Avenue, New York, NY 10016, United States. Electronic address: [email protected].
Abstract

To illuminate the tolerance of fluoroalkoxylated groups at the C-3 and C-9 positions of tetrahydroprotoberberines (THPBs) on D1R activity, C-3 and C-9 fluoroalkoxylated analogues of (S)-12-bromostepholidine were prepared and evaluated. All compounds examined were D1R antagonists as measured by a cAMP assay. Our structure-activity studies herein indicate that the C-3 position tolerates a 1,1-difluoroethoxy substituent for D1R antagonist activity. Compound 13a was the most potent cAMP-based D1R antagonist identified and was also found to antagonize β-arrestin translocation in a TANGO assay. Affinity assessments at Other dopamine receptors revealed that 13a is selective for D1R and unlike Other naturally-occurring THPBs such as (S)-stepholidine, lacks D2R affinity. In preliminary biopharmaceutical assays, excellent BBB permeation was observed for 13a. Further pharmacological studies are warranted on (S)-stepholidine congeners to harvest their potential as a source of novel, druggable D1R-targeted agents.

Keywords
D1R; Dopamine; Stepholidine; THPB; Tetrahydroprotoberberine; β-Arrestin.
Products